Also known as: HCD122
Drug Information: Lucatumumab is one of several experimental anti-CD40 monoclonal antibodies. CD40 is a cellular surface protein involved in immune system signaling, which is present on cancerous B cells. The drug's developer, Novartis, believes that it both blocks proliferation of malignant cells and attracts other immune system cells to attack the cancer. It is given intravenously on a weekly basis for multi-week treatment cycles.
Lucatumumab is a fully human antibody, meaning it may cause less adverse reactions than mouse-based and chimeric antibodies already in use.
Side Effects: No information yet.
Clinical Trials: A Phase I/II trial for follicular lymphoma patients was initiated by Novartis in 2010 and is listed on ClinicalTrials.gov. It involves lucatumumab given in combination with bendamustine.
A Phase I/II clinical trial in 79 lymphoma patients, including follicular lymphoma patients, reported a 40% response rate in patients who failed to respond to rituximab. In 49 patients given the maximum tolerable dose, 4 of 12 (33%) of follicular lymphoma patients responded to lucatumumab monotherapy, including one who achieved complete remission.
Published Studies
Arnold S. Freedman et al. "Clinical Activity of Lucatumumab (HCD122)." ASH Annual Meeting (December 2010).
Hello,
ReplyDeleteYou have provided a very good site to knowing about Monoclonal antibody. These antigen used to generate the antibody is covalently attached to an agarose support, which is produce a single type of antibody that binds to a corresponding antigen. Thanks a lot for creating this type of valuable site....
I find many useful things herewith. It is really amazing for us. Where ever we are, just click on the website and Take advantage .Your article impressed me very heartily. From a last decade I was searching such type of website. Thanks for giving me a space in your blog. I refer this to my close friends who are already seeking for the same .Thanks again guys…
ReplyDeletemonoclonal antibodies